Suppr超能文献

双重 BET/BRPF1 抑制剂增强肝癌和乳腺癌细胞的细胞死亡。

Enhanced cellular death in liver and breast cancer cells by dual BET/BRPF1 inhibitors.

作者信息

Cazzanelli Giulia, Dalle Vedove Andrea, Sbardellati Nicolò, Valer Luca, Caflisch Amedeo, Lolli Graziano

机构信息

Department of Cellular, Computational and Integrative Biology-CIBIO, University of Trento, Trento, Italy.

Department of Biochemistry, University of Zürich, Zürich, Switzerland.

出版信息

Protein Sci. 2024 Nov;33(11):e5191. doi: 10.1002/pro.5191.

Abstract

The acetylpyrrole scaffold is an acetylated lysine mimic that has been previously explored to develop bromodomain inhibitors. When tested on the hepatoma cell line Huh7 and the breast cancer cell line MDA-MB-231, a few compounds in our acetylpyrrole-thiazole library induced peculiar morphological changes, progressively causing cell death at increasing concentrations. Their evaluation on a panel of human bromodomains revealed concurrent inhibition of BRPF1 and BET bromodomains. To dissect the observed cellular effects, the acetylpyrrole derivatives were compared to JQ1 and GSK6853, chemical probes for the bromodomains of BET and BRPF1, respectively. The appearance of neurite-like extrusions, accompanied by βIII-tubulin overexpression, is caused by BET inhibition, with limited effect on cellular viability. Conversely, interference with BRPF1 induces cellular death but not phenotypic alterations. Combined treatment with JQ1 and GSK6853 showed additivity in reducing cellular viability, comparably to the acetylpyrrole-thiazole-based BET/BRPF1 inhibitors. In addition, we determined the crystallographic structures of the BRD4 and BRPF1 bromodomains in complex with the acetylpyrrole-thiazole compounds. The binding modes in the two bromodomains show similar interactions for the acetylpyrrole and different orientations of the moiety that point to the rim of the acetyl-lysine pocket.

摘要

乙酰吡咯骨架是一种乙酰化赖氨酸类似物,此前曾被用于开发溴结构域抑制剂。当在肝癌细胞系 Huh7 和乳腺癌细胞系 MDA-MB-231 上进行测试时,我们的乙酰吡咯-噻唑库中的一些化合物诱导了奇特的形态变化,随着浓度的增加逐渐导致细胞死亡。它们在一系列人类溴结构域上的评估显示出对 BRPF1 和 BET 溴结构域的同时抑制。为了剖析观察到的细胞效应,将乙酰吡咯衍生物与 JQ1 和 GSK6853 进行了比较,JQ1 和 GSK6853 分别是 BET 和 BRPF1 溴结构域的化学探针。神经元样突起的出现伴随着 βIII-微管蛋白的过表达,这是由 BET 抑制引起的,对细胞活力的影响有限。相反,干扰 BRPF1 会诱导细胞死亡,但不会引起表型改变。JQ1 和 GSK6853 的联合治疗在降低细胞活力方面表现出相加作用,与基于乙酰吡咯-噻唑的 BET/BRPF1 抑制剂相当。此外,我们还确定了 BRD4 和 BRPF1 溴结构域与乙酰吡咯-噻唑化合物复合物的晶体结构。这两个溴结构域中的结合模式显示出对乙酰吡咯的相似相互作用,以及指向乙酰赖氨酸口袋边缘的部分的不同取向。

相似文献

2
Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Proc Natl Acad Sci U S A. 2021 Mar 2;118(9). doi: 10.1073/pnas.2021102118.
3
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Nature. 2020 Feb;578(7794):306-310. doi: 10.1038/s41586-020-1930-8. Epub 2020 Jan 22.
4
BET bromodomain inhibition of MYC-amplified medulloblastoma.
Clin Cancer Res. 2014 Feb 15;20(4):912-25. doi: 10.1158/1078-0432.CCR-13-2281. Epub 2013 Dec 2.
5
Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
Science. 2014 Oct 31;346(6209):638-641. doi: 10.1126/science.1249830. Epub 2014 Oct 16.
6
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
ACS Chem Biol. 2020 Apr 17;15(4):1036-1049. doi: 10.1021/acschembio.0c00058. Epub 2020 Mar 23.
7
Zinc-chelating BET bromodomain inhibitors equally target islet endocrine cell types.
Am J Physiol Regul Integr Comp Physiol. 2024 Jun 1;326(6):R515-R527. doi: 10.1152/ajpregu.00259.2023. Epub 2024 Apr 15.
8
Bromodomains: Structure, function and pharmacology of inhibition.
Biochem Pharmacol. 2016 Apr 15;106:1-18. doi: 10.1016/j.bcp.2015.12.005. Epub 2015 Dec 18.
9
4-Methyl-1,2,3-Triazoles as -Acetyl-Lysine Mimics Afford Potent BET Bromodomain Inhibitors with Improved Selectivity.
J Med Chem. 2021 Jul 22;64(14):10497-10511. doi: 10.1021/acs.jmedchem.1c00933. Epub 2021 Jul 8.
10
Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines.
Bioorg Med Chem. 2024 Oct 1;112:117884. doi: 10.1016/j.bmc.2024.117884. Epub 2024 Aug 31.

引用本文的文献

1
Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications.
Front Pharmacol. 2025 Jun 18;16:1589455. doi: 10.3389/fphar.2025.1589455. eCollection 2025.

本文引用的文献

1
Reevaluation of bromodomain ligands targeting BAZ2A.
Protein Sci. 2023 Sep;32(9):e4752. doi: 10.1002/pro.4752.
2
BET proteins: Biological functions and therapeutic interventions.
Pharmacol Ther. 2023 Mar;243:108354. doi: 10.1016/j.pharmthera.2023.108354. Epub 2023 Feb 3.
3
Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
ACS Med Chem Lett. 2022 Aug 3;13(9):1434-1443. doi: 10.1021/acsmedchemlett.2c00173. eCollection 2022 Sep 8.
5
BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
EMBO Rep. 2021 Nov 4;22(11):e53014. doi: 10.15252/embr.202153014. Epub 2021 Aug 17.
6
Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer.
Commun Biol. 2021 Jul 20;4(1):888. doi: 10.1038/s42003-021-02405-6.
7
4-Acyl Pyrroles as Dual BET-BRD7/9 Bromodomain Inhibitors Address BETi Insensitive Human Cancer Cell Lines.
J Med Chem. 2020 Dec 24;63(24):15603-15620. doi: 10.1021/acs.jmedchem.0c00478. Epub 2020 Dec 4.
8
Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.
Blood Adv. 2020 Sep 8;4(17):4124-4135. doi: 10.1182/bloodadvances.2020001879.
10
Targeting epigenetic reader domains by chemical biology.
Curr Opin Chem Biol. 2020 Aug;57:82-94. doi: 10.1016/j.cbpa.2020.05.006. Epub 2020 Jul 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验